MYOS CORP Announces Positive Results from Feline Study on Fortetropin prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
MYOS CORP Enters Exclusive Agreement with Science Biotech to Distribute Fortetropin® Products in Australia and New Zealand
News provided by
Share this article
CEDAR KNOLLS, N.J., Dec. 21, 2020 /PRNewswire/
MYOS CORP ( MYOS or the Company ), a research-based advanced nutrition company with divisions that address both
Human Nutrition and
Science Biotech to exclusively distribute its
Fortetropin
® products in Australia and New Zealand. Fortetropin is a proprietary advanced nutrition product developed and owned by MYOS that has been shown in multiple human and veterinary clinical studies to accelerate gains in muscle mass, improve mobility, and enhance recovery from injury. We are very pleased to announce our partnership with Science Biotech. In Science Biotech we found a partner that is incredibly passionate about our products. Due to its sporting culture and love of pets, Australia was identified as a key market for us, and we couldn t be happier with the fit we
Share this article
CEDAR KNOLLS, N.J., Dec. 15, 2020 /PRNewswire/
MYOS CORP ( MYOS or the Company ), is a research-based advanced nutrition company with divisions that address both
Human Nutrition and
Fortetropin
®, a proprietary advanced nutrition product developed and owned by MYOS, that has been shown in multiple veterinary and human clinical studies to accelerate gains in muscle mass, improve mobility and enhance recovery from injury.
On November 17, 2020, Nasdaq-listed Myos Rens Technology, Inc. ( MYOS RENS ) consummated the previously announced merger of its wholly owned subsidiary with and into MedAvail, Inc., a privately held Delaware corporation (the Merger ), after which MYOS RENS was renamed MedAvail Holdings, Inc. ( MedAvail ) and the stock symbol of the company was changed to MDVL.